Chagas disease
diseaseOn this page
Also known as Chagas' diseaseinfection by trypanosoma cruziTrypanosoma cruzi caused disease or disorderTrypanosoma cruzi disease or disorderTrypanosoma cruzi infectious disease
Summary
Chagas disease (MONDO:0001444) is a disease and 59 clinical trials. Top therapeutic interventions include benznidazole, nifurtimox, and enalapril. A subtype of trypanosomiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 6-9 / 10 000 (United States) [Orphanet-validated]
- Phenotypes (HPO): 27
- Clinical trials: 59
Clinical features
Epidemiology
Prevalence records
11 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 6-9 / 10 000 | 95 | United States | Validated |
| Point prevalence | 1-9 / 1 000 000 | Europe | Not yet validated | |
| Point prevalence | 1-9 / 1 000 000 | France | Not yet validated | |
| Point prevalence | <1 / 1 000 000 | Germany | Not yet validated | |
| Point prevalence | 1-9 / 1 000 000 | Italy | Not yet validated | |
| Point prevalence | <1 / 1 000 000 | Netherlands | Not yet validated | |
| Point prevalence | <1 / 1 000 000 | Portugal | Not yet validated | |
| Point prevalence | 1-9 / 100 000 | Spain | Not yet validated | |
| Point prevalence | 1-9 / 100 000 | Switzerland | Not yet validated | |
| Point prevalence | <1 / 1 000 000 | United Kingdom | Not yet validated | |
| Point prevalence | 1-9 / 1 000 000 | Belgium | Not yet validated |
Signs & symptoms
Clinical features (HPO)
27 HPO clinical features (Orphanet curated; top 27 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000969 | Edema | Frequent (30-79%) |
| HP:0000980 | Pallor | Frequent (30-79%) |
| HP:0000988 | Skin rash | Frequent (30-79%) |
| HP:0001638 | Cardiomyopathy | Frequent (30-79%) |
| HP:0001744 | Splenomegaly | Frequent (30-79%) |
| HP:0001907 | Thromboembolism | Frequent (30-79%) |
| HP:0001945 | Fever | Frequent (30-79%) |
| HP:0002014 | Diarrhea | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002094 | Dyspnea | Frequent (30-79%) |
| HP:0002240 | Hepatomegaly | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002716 | Lymphadenopathy | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0011355 | Localized skin lesion | Frequent (30-79%) |
| HP:0011675 | Arrhythmia | Frequent (30-79%) |
| HP:0012735 | Cough | Frequent (30-79%) |
| HP:0012819 | Myocarditis | Frequent (30-79%) |
| HP:0030057 | Autoimmune antibody positivity | Frequent (30-79%) |
| HP:0100539 | Periorbital edema | Frequent (30-79%) |
| HP:0001635 | Congestive heart failure | Occasional (5-29%) |
| HP:0002251 | Aganglionic megacolon | Occasional (5-29%) |
| HP:0002571 | Achalasia | Occasional (5-29%) |
| HP:0012700 | Abnormal large intestine physiology | Occasional (5-29%) |
| HP:0000707 | Abnormality of the nervous system | Very rare (<1-4%) |
| HP:0002383 | Infectious encephalitis | Very rare (<1-4%) |
| HP:0009830 | Peripheral neuropathy | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Chagas disease |
| Mondo ID | MONDO:0001444 |
| MeSH | D014355 |
| Orphanet | 3386 |
| DOID | DOID:12140 |
| ICD-10-CM | B57 |
| ICD-11 | 1365585570 |
| NCIT | C84629 |
| SNOMED CT | 77506005 |
| UMLS | C0041234 |
| MedGen | 11935 |
| GARD | 0018795 |
| MedDRA | 10001935 |
| Is cancer (heuristic) | no |
Also known as: Chagas disease · Chagas’ disease · infection by trypanosoma cruzi · Trypanosoma cruzi caused disease or disorder · Trypanosoma cruzi disease or disorder · Trypanosoma cruzi infectious disease
Disease family
This is a subtype of trypanosomiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › trypanosomiasis › Chagas disease
Related subtypes (1): human African trypanosomiasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Benznidazole | Approved (phase 4) |
| Nifurtimox | Approved (phase 4) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atorvastatin, Fexinidazole, Posaconazole.
Clinical trials & evidence
Clinical trials
Clinical trials: 59.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 26 |
| PHASE3 | 9 |
| PHASE2 | 9 |
| PHASE4 | 7 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01006473 | PHASE4 | COMPLETED | Exercise Training in Chagas Cardiomyopathy |
| NCT01006486 | PHASE4 | COMPLETED | Outcomes of an Anticoagulation Clinic in an University Hospital |
| NCT01539161 | PHASE4 | TERMINATED | Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease |
| NCT01549236 | PHASE4 | COMPLETED | Population Pharmacokinetics Study of Benznidazole in Children With Chagas’Disease |
| NCT01678599 | PHASE4 | COMPLETED | Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease |
| NCT01755403 | PHASE4 | COMPLETED | Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease |
| NCT04023227 | PHASE4 | COMPLETED | Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC |
| NCT04024163 | PHASE3 | ACTIVE_NOT_RECRUITING | Prospective Study of Benznidazole for Chagas’ Disease Children With Chronic Indeterminate Chagas Disease |
| NCT04897516 | PHASE3 | RECRUITING | Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease |
| NCT00123916 | PHASE3 | COMPLETED | BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas’ Disease |
| NCT00875173 | PHASE3 | UNKNOWN | Selenium Treatment and Chagasic Cardiopathy (STCC) |
| NCT02369978 | PHASE2/PHASE3 | UNKNOWN | CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) |
| NCT02386358 | PHASE3 | COMPLETED | Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial |
| NCT02516293 | PHASE2/PHASE3 | COMPLETED | Cardiac Rehabilitation in Chagas Heart Failure |
| NCT02517632 | PHASE3 | COMPLETED | Physical Exercise Program in Chronic Chagas Heart Disease |
| NCT02625974 | PHASE3 | COMPLETED | A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas’ Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi |
| NCT03672487 | PHASE3 | COMPLETED | Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age |
| NCT06339710 | PHASE3 | WITHDRAWN | Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients |
| NCT04984265 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | SBRT in Chagas Disease Ventricular Tachycardia |
| NCT06632600 | PHASE2 | RECRUITING | A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. |
| NCT01162967 | PHASE2 | COMPLETED | Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole |
| NCT01377480 | PHASE2 | COMPLETED | A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) |
| NCT02498782 | PHASE2 | UNKNOWN | Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease |
| NCT03191162 | PHASE2 | COMPLETED | Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. |
| NCT03378661 | PHASE2 | UNKNOWN | BENDITA BEnznidazole New Doses Improved Treatment and Associations |
| NCT03704181 | PHASE2 | UNKNOWN | Colchicine for Patients With Chagas´ Disease( B1 Stage) |
| NCT03981523 | PHASE2 | COMPLETED | New Therapies and Biomarkers for Chagas Infection |
| NCT04984616 | PHASE2 | TERMINATED | Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease |
| NCT01927224 | PHASE1 | COMPLETED | Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas’ Patients |
| NCT02606864 | PHASE1 | COMPLETED | Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas’ Patients |
| NCT03334838 | PHASE1 | COMPLETED | Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas’ Patients - Dietary Habits Study |
| NCT03350295 | PHASE1 | COMPLETED | Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg |
| NCT03892213 | PHASE1 | COMPLETED | Pharmacokinetic Drug-Drug Interaction Study |
| NCT05477953 | Not specified | NOT_YET_RECRUITING | An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother’s and Baby’s Health |
| NCT07033325 | Not specified | ENROLLING_BY_INVITATION | University-Based Chagas Testing in Salta Province, Argentina |
| NCT00005455 | Not specified | COMPLETED | Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States |
| NCT00023556 | Not specified | COMPLETED | Genetic Architecture of Heart Disease in Rural Brazil |
| NCT00453700 | Not specified | COMPLETED | Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram |
| NCT00699387 | Not specified | COMPLETED | Population Pharmacokinetics of Benznidazole in Children With Chagas Disease |
| NCT01547533 | Not specified | COMPLETED | Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BENZNIDAZOLE | 4 | 17 |
| NIFURTIMOX | 4 | 4 |
| ENALAPRIL | 4 | 3 |
| POSACONAZOLE | 4 | 2 |
| FEXINIDAZOLE | 4 | 1 |
| SACUBITRIL | 4 | 1 |
| VALSARTAN | 4 | 1 |
| SELENIUM | 3 | 1 |
| LXE-408 | 2 | 1 |
| CHEMBL1486475 | 0 | 4 |
Related Atlas pages
- Drugs: Benznidazole, Nifurtimox, Enalapril, Posaconazole, Fexinidazole, Sacubitril, Valsartan